Market Overview

OTC Stock Review Issues Updated Report on Medical Marijuana, Inc.


ATLANTA, Oct. 31, 2012 (GLOBE NEWSWIRE) -- OTC Stock Review announces that it has published an updated report on Medical Marijuana, Inc. (OTC: MJNA) which was originally issued at $0.04 per share on May 4, 2012. In our opinion, the Medical Marijuana industry is still in its infancy and we are just now starting to see leaders like MJNA emerge. Investors who follow our newsletter know we are always in search of the ever elusive 10-Bagger, or a stock that has the potential to make investors 10 times their money.

One of MJNA's portfolio companies, PhytoSPHERE Systems, which develops pharmaceutical grade hemp production facilities that produce high grade oil, announced the harvest of approximately 1,000 acres of Hemp from its microclimate fields in Europe. A September 18 San Francisco Chronicle Article, "Pot compound seen as tool against cancer" mentions CBD. According to the article, scientists at California Pacific Medical Center found that Cannabidiol, or CBD, has the ability to "turn off" the DNA that causes "breast and other types of cancers" to metastasize.

Investors can download the report on our website, free of charge at

NOTE: The purpose of this release is to introduce the reader to and Medical Marijuana, Inc. OTC Stock Review is not a Registered Investment Advisor or a Broker/Dealer. Information and opinions presented in this release are solely for informative purposes and not intended, nor should they be construed as, investment advice. This document contains information obtained from public sources about Medical Marijuana, Inc., but does not contain all the relevant material information necessary to evaluate the company. This release is not to be considered an offer to buy, sell, hold, and/or otherwise trade in the securities of Medical Marijuana, Inc., as profiled. OTC Stock Review has been compensated One Thousand five Hundred Dollars by a third party to update this report. Officers, directors, and employees of OTC Stock Review, may hold a long or short equity position of a profiled Company and may trade in these securities for their own accounts. Carefully review profiled companies with your investment advisor, stockbroker, or other such professional. OTC Stock Review is not liable for any investment decisions by its readers or their advisors. Any analysis contained herein does not purport to be a complete analysis of the profiled companies. Readers are encouraged to obtain copies of the profiled Company's periodic reports filed with United States Securities and Exchange Commission, which are generally available at You can view our complete disclaimer at

CONTACT: OTC Stock Review David Kugelman 404-281-8556


View Comments and Join the Discussion!